Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 18:13:17588359211015499.
doi: 10.1177/17588359211015499. eCollection 2021.

Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program

Fernando Sabino M Monteiro  1 , Adriano Gonçalves E Silva  2 , Andrea Juliana P de S Gomes  3 , Carolina Dutra  4 , Naira Oliveira Ferreira  5 , Rodrigo Coutinho Mariano  6 , Fabio A Schutz  7
Affiliations

Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program

Fernando Sabino M Monteiro et al. Ther Adv Med Oncol. .

Abstract

Background: Erdafitinib is the first targeted therapy approved for the treatment of patients with metastatic urothelial carcinoma (mUC). Approval was based on a phase II single-arm trial that demonstrated significant activity of erdafitinib in patients with tumors harboring FGFR2/3 alterations. In Brazil, an Expanded Access Program (EAP) provided patients with early access to erdafitinib prior to market authorization. The current report describes characteristics and outcomes of patients with mUC on erdafitinib therapy.

Methods: Patients with mUC that failed first- and second-line systemic therapies were screened for FGFR2/3 alterations in primary or metastatic tumor tissues. Patients with FGFR2/3 alterations were selected to receive erdafitinib at the standard dosing schedule and were followed prospectively to evaluate the efficacy and safety outcomes.

Results: From 19 April 2019, through 13 March 2020, 47 patients with mUC from 10 Brazilian centers were tested for FGFR2/3 alterations. Alterations in FGFR2/3 were found in 12 patients (25.5%) and all of them were eligible for the EAP. Four patients (33%) had partial response, while two patients (17%) had stable disease. Progressive disease, the best response, was observed in five patients (42%). At a median follow-up of 16.2 months, the median time to treatment failure (TTF) was 2.8 months. When considering only patients with objective response, the median TTF was 5.3 months. Adverse events (AEs) were reported for any grade and grade 3 or higher in 10 patients (83%) and 5 patients (42%), respectively. The most common AE was hyperphosphatemia.

Conclusion: This first real-world evidence report of heavily treated patients with mUC confirms the efficacy and safety of erdafitinib in a disease setting with a lack of treatment options.

Keywords: advanced disease; erdafitinib; real-world evidence; targeted therapy; urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare research support from Janssen; honoraria from Janssen, Astellas, Roche, MSD and BMS; and advisory board roles for Janssen, BMS and MSD.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30. - PubMed
    1. Flaig TW, Spiess PE, Agarwal N, et al.. Bladder cancer, version 3. 2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020; 18: 329–354. - PubMed
    1. Oing C, Rink M, Oechsle K, et al.. Second-line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond-a comprehensive review of the current literature. J Urol 2016; 195: 254–263. - PubMed
    1. Bellmunt J, de Wit R, Vaughn DJ, et al.. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015–1026. - PMC - PubMed
    1. Powles T, Durán I, van der Heijden MS, et al.. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748–757. - PubMed

LinkOut - more resources